



## ASX ANNOUNCEMENT

18 October 2007

### **New VitroGro® Formulation & Patent Applications**

**Tissue Therapies Limited (ASX: TIS)** is delighted to announce another enhancement of the VitroGro® technology platform, with the development of a new formulation of VitroGro® and two new patent applications.

The new VitroGro® formulation is highly biologically active and stable and offers major commercial benefits to Tissue Therapies in reduced manufacturing costs and enhanced intellectual property position.

In terms of manufacturing costs alone, the new formulation of VitroGro® is expected to reduce production costs by at least 50%.

Tissue Therapies CEO Dr Steven Mercer said, "once again, an impressive series of world class protein science achievements from the TT/QUT research and development team headed by Professor Zee Upton will deliver significant technical and commercial benefits to Tissue Therapies."

"The new formulation of VitroGro® will not only greatly simplify large scale manufacturing, but by lowering the costs of the VitroGro® technology will enhance Tissue Therapies' future profitability as well as enable the sale of VitroGro® for large scale industrial applications that may not have been feasible with the earlier, more expensive formulations."

Also announced today are two new VitroGro® patent applications.

The first of these is for a method of using VitroGro® in combination with a synthetic, proprietary technology from a research collaboration partner for the successful culture of human embryonic stem cells with no human or animal proteins and no feeder cells. Prof Zee Upton, the Chief Scientific Officer of Tissue Therapies said, "As far as I am aware, the culture of human embryonic stem cells without human or animal proteins and particularly with no feeder cell layer has not been achieved before."

The presence of animal and human proteins and feeder cells has been a fundamental impediment in gaining regulatory approval to offer stem cell derived therapies for human treatment.

Cont/ 2...

The second new patent application is for a method of using a hydrogel dressing in combination with an already approved pharmaceutical for the removal and inactivation of inflammatory factors that prevent healing in chronic wounds. Dr Mercer said, "This is a highly complementary technology that has the potential to enhance the action of VitroGro® in accelerating the healing of chronic wounds and we will certainly include this in our ongoing negotiations with international wound care companies."

He went on to say "these announcements continue the scientific and commercial enhancement of the VitroGro® technology platform and future shareholder value."

Further information: Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: 07 3839 9938  
  
s.mercer@tissuetherapies.com

***ENDS***

### **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)**